Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel

BACKGROUND: In the AFFIRM trial, enzalutamide significantly increased overall survival (OS) for men with metastatic castration‐resistant prostate cancer (mCRPC) after chemotherapy versus placebo and significantly decreased prostate‐specific antigen (PSA) levels. The goal of this post hoc analysis wa...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer
Auteurs principaux: Armstrong, Andrew J., Saad, Fred, Phung, De, Dmuchowski, Carl, Shore, Neal D., Fizazi, Karim, Hirmand, Mohammad, Forer, David, Scher, Howard I., Bono, Johann De
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2017
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5484320/
https://ncbi.nlm.nih.gov/pubmed/28171710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30587
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires